Skip to main navigation
  • Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Scholar Rock, Inc. Logo

Scholar Rock, Inc.

  • Careers
  • Newsroom
  • Contact Us
  • Patients & Families
    • Patients & Families
    • Areas of Focus
      • Spinal Muscular Atrophy
    • Patient Stories
    • Clinical Trials
    • Resources
    • Expanded Access

    Learn about our commitment to creating possibilities for those living with serious disease.

    Patients & Families

  • Our Company
    • Our Company
    • Mission & Vision
    • Newsroom
    • Careers
    • Management Team
    • Board of Directors

    Meet Scholar Rock, a biopharmaceutical company committed to improving lives.

    Our Company

  • Our Science
    • Our Science
    • Platform
    • Publications & Posters

    Discover how our breakthrough approach treats complex disease at its biological root.

    Our Science

  • Our Pipeline
    • Our Pipeline
    • Neuromuscular and Obesity
      • Spinal Muscular Atrophy
    • Cardiometabolic Disorders
    • Immuno-Oncology
      • Cancer (solid tumors)
    • Fibrotic Diseases
      • Fibrosis
    • Hematology
      • Anemia
  • Investors & Media
    • Investors & Media
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR or Media
Link to homepage Investors & Media Financials & Filings

Investors and Media

Financials & Filings

Main content section

Annual Reports

2024 Annual Report
7.07 MB
2023 Annual Report
12.77 MB
2022 Annual Report
3.01 MB
2021 Annual Report
5.25 MB
2020 Annual Report
3.3 MB
2019 Annual Report
4.81 MB
2018 Annual Report
3.22 MB
Filing Date Description Form Filing Group View
March 31, 2026 Report of unscheduled material events or corporate event 8-K
Current Reports
View HTML
0001104659-26-037350.pdf
0001104659-26-037350.rtf
0001104659-26-037350.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
March 27, 2026 SCHEDULE 13G/A - Description SCHEDULE 13G/A
Other
View HTML
0000102909-26-002255.pdf
0000102909-26-002255.rtf
0000102909-26-002255.xls
March 3, 2026 Report of unscheduled material events or corporate event 8-K
Current Reports
View HTML
0001104659-26-022547.pdf
0001104659-26-022547.rtf
0001104659-26-022547.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
March 3, 2026 Annual report which provides a comprehensive overview of the company for the past year 10-K
Annual Filings
View HTML
0001104659-26-022551.pdf
0001104659-26-022551.rtf
0001104659-26-022551.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
March 3, 2026 Securities offered to employees pursuant to employee benefit plans S-8
Registration Statements
View HTML
0001104659-26-022553.pdf
0001104659-26-022553.rtf
0001104659-26-022553.xls
XML - XBRL INSTANCE DOCUMENT
March 3, 2026 Amendment to a previously filed 8-K 8-K/A
Current Reports
View HTML
0001104659-26-022897.pdf
0001104659-26-022897.rtf
0001104659-26-022897.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
February 25, 2026 Statement of changes in beneficial ownership of securities 4
3,4,5
View HTML
0001104659-26-019789.pdf
0001104659-26-019789.rtf
0001104659-26-019789.xls
February 23, 2026 Filed by "insiders" prior intended sale of restricted stock. 144
Other
View HTML
0001968582-26-000143.pdf
0001968582-26-000143.rtf
0001968582-26-000143.xls
February 19, 2026 Statement of changes in beneficial ownership of securities 4
3,4,5
View HTML
0001922346-26-000004.pdf
0001922346-26-000004.rtf
0001922346-26-000004.xls
February 19, 2026 Statement of changes in beneficial ownership of securities 4
3,4,5
View HTML
0001868114-26-000004.pdf
0001868114-26-000004.rtf
0001868114-26-000004.xls
  • Current page 1
  • Page 2
  • Page 3
  • …
  • Next page ›
  • Last page »

Data provided by Kaleidoscope.

Primary Sidebar

Investor Menu

  • Investors & Media
  • Press Releases
    • Archived Press Releases
  • Events & Presentations
  • Corporate Governance
    • Management Team
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
  • Stock Information
    • Historical Stock Lookup
    • Investment Calculator
    • Analyst Coverage
  • Investor FAQs
  • Contact IR or Media

In this section

Footer

Scholar Rock, Inc.
301 Binney Street, 3rd Floor
Cambridge, MA 02142

Phone: 857.259.3860
info@scholarrock.com

© 2026 All Rights Reserved
  • Community Guidelines
  • Expanded Access Policy
  • Privacy Policy
  • Terms of Use

We are Scholar Rock.

A biopharmaceutical company dedicated to discovering, developing, and delivering therapies that create new possibilities for patients.

Learn More About Our Pipeline

  • Community Guidelines
  • Expanded Access Policy
  • Privacy Policy
  • Terms of Use
Scholar Rock, Inc. Logo
  • Patients & Families
    • Areas of Focus
      • Spinal Muscular Atrophy
    • Patient Stories
    • Clinical Trials
    • Resources
    • Expanded Access
  • Our Company
    • Our Company
    • Mission & Vision
    • Newsroom
    • Careers
    • Management Team
    • Board of Directors
  • Our Science
    • Our Science
    • Platform
    • Publications & Posters
  • Our Pipeline
    • Neuromuscular and Obesity
      • Spinal Muscular Atrophy
    • Immuno-Oncology
      • Cancer (solid tumors)
      • Fibrotic Diseases
    • Hematology
      • Anemia
  • Investors & Media
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR or Media
  • Careers
  • Newsroom
  • Contact Us